SIONNA THERAPEUTICS, INC. Operating Cash Flow
SIONNA THERAPEUTICS, INC. (SION) reported Operating Cash Flow of -$44.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$22.22M.
- SIONNA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$21.84M.
- SIONNA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$16.63M.
- SIONNA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$15.23M.
- SIONNA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$66.30M.
- SIONNA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$52.79M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$44.06M 10-Q · filed 2026-08-06 | -$60.69M derived: sum of 3 quarters · filed 2026-08-06 | -$75.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$21.84M 10-Q · filed 2026-05-12 | -$38.47M derived: sum of 2 quarters · filed 2026-05-12 | -$53.70M derived: sum of 3 quarters · filed 2026-05-12 | -$71.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$16.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$31.86M derived: sum of 2 quarters · filed 2026-03-02 | -$50.01M derived: sum of 3 quarters · filed 2026-08-06 | -$66.30M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$15.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$33.38M derived: sum of 2 quarters · filed 2026-08-06 | -$49.67M 10-Q · filed 2025-11-05 | -$61.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$18.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$34.44M 10-Q · filed 2026-08-06 | -$46.22M derived: sum of 3 quarters · filed 2026-08-06 | -$63.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$16.29M 10-Q · filed 2026-05-12 | -$28.07M derived: sum of 2 quarters · filed 2026-05-12 | -$45.76M derived: sum of 3 quarters · filed 2026-05-12 | -$55.90M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$11.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$29.47M derived: sum of 2 quarters · filed 2026-03-02 | -$39.61M derived: sum of 3 quarters · filed 2026-03-02 | -$52.79M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$17.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$27.83M derived: sum of 2 quarters · filed 2025-11-05 | -$41.01M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$10.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$23.32M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$13.18M 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |